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Cutaneous Features Predict Paraspinal 
Neurofibromas in Neurofibromatosis Type 1
Rebecca M. Brown1,2, Laura J. Klesse3,4 and Lu Q. Le1,2,4
In neurofibromatosis type 1 (NF-1), malignant transformation of internal plexiform 
neurofibromas carries a poor prognosis, in part because they are not evident clini-
cally. In this issue, Sbidian et al. describe a novel “NF-1Score” equation that employs 
four easily observable traits to predict the presence of paraspinal neurofibromas. This 
tool can identify at-risk patients during regular screening to help reduce mortality.
Journal of Investigative Dermatology (2010) 130, 2167–2169. doi:10.1038/jid.2010.206
neurofibromatosis type 1  
and risk of malignancy
Von Recklinghausen’s neurofibro matosis 
type 1 (NF-1) is one of the most com-
mon autosomal dominant cancer-pre-
disposing genetic disorders, affecting 
one in 3,000 individuals. NF-1 results 
from a mutation in the tumor suppressor 
gene neuro fibromin. Spontaneous loss of 
function of the healthy NF-1 allele in the 
neural crest stem cell lineage leads to a 
wide spectrum of clinical presentations, 
including developmental pigmentary 
and neoplastic aberrations. The cardi-
nal features of NF-1 include café-au-lait 
macules, axillary and groin freckling, 
bone abnormalities, and peripheral nerve 
tumors. Neurofibromas are the most com-
mon NF-1 tumors, and they may take 
several forms. Cutaneous neuro fibromas 
are the most frequent, usually appearing 
at puberty; they are benign and typically 
undergo self-limited growth. On the 
other hand, deep-tissue and plexiform 
neuro fibromas are thought to be primar-
ily congenital lesions that carry a 10% 
risk of malignant transformation. The 
resulting malignant peripheral nerve-
sheath tumors (MPNSTs) can metastasize 
widely and often portend a fatal outcome. 
The risk of malignant transformation is 
as much as 18 times higher for internal 
compared with cutaneous neurofibromas. 
Deep-tissue neuro fibromas occur in 
20–40% of adult NF-1 patients (Tonsgard 
et al., 1998). The majority of internal 
plexiform neurofibromas manifest in the 
para spinal region at the neural foramina 
of the vertebral column associated with 
dorsal root ganglia, and they are com-
monly asymptomatic. Clinically, the iden-
tification of patients who are most likely 
to harbor paraspinal neurofibromas (those 
who are at highest risk for malignancy) is 
problematic.
Barriers to early diagnosis of mPnSt
MPNSTs, especially in patients with NF-1, 
confer a high mortality rate because of 
their propensity to metastasize, resis-
tance to chemotherapy, and mitotic 
response to irradiation. Even with surgi-
cal treatment, the 5-year survival rate 
is at or below 50% (Wong et al., 1998). 
Radical excision of small, internal neu-
rofibromas is efficacious immediately 
after MPNST development, but resection 
carried out long after malignant conver-
sion eliminates the MPNST only 20% 
of the time (Gupta and Maniker, 2007). 
Relapse is common, potentially because 
of tumor hetero geneity, which confounds 
histopathological tissue sampling and 
results in inaccurate assessment of tumor 
diameters. Although pain and other neu-
ropathies are frequently cited as the most 
common chief complaints, patients with 
internal MPNSTs may remain asymptom-
atic until the lesions reach a life-threaten-
ing size. At the same time, magnetic reso-
nance imaging and computer tomography 
scans readily identify paraspinal, abdomi-
nal, pelvic, and thoracic neurofibromas, 
but they cannot identify malignancy, and 
they are not part of routine patient vis-
its, in large part because neurofibromas 
often remain asymptomatic and benign 
throughout a patient’s life. Recently, 
fluorodeoxyglucose–positron emission 
tomography (FDG-PET) scans have been 
utilized to identify neurofibromas exhibit-
ing increased metabolism, which is indic-
ative of a high mitotic rate and correlates 
with malignant transformation. FDG-PET 
scans of confirmed MPNST growth have 
also been correlated with patient out-
come, and they are recommended as a 
surveillance technique in monitoring the 
transition to a malignant state (Brenner et 
al., 2006). This method is now used clini-
cally to track the development of candi-
date MPNSTs over time. Thus, a reliable 
method of predicting which patients are 
at greatest risk for developing internal 
neurofibromas would justify routine PET 
scan screens in those patients.
Despite the high risk of mortal-
ity should a malignant transformation 
be missed, NF-1 patients have relatively 
poor adherence to regular check-ups 
with their primary care providers. Adult 
NF-1 patients may neglect appointments 
because of a lack of treatment options, 
given that no pharmaceutical agents have 
demonstrated efficacy in reducing the size 
or number of NF-1-associated tumors. 
The remaining treatment option—surgical 
excision of painful, pruritic, or cosmetical-
ly displeasing neurofibromas—may leave 
unsightly scars, affect nerve function, and 
fail to cure the ailment. Indeed, a recent 
survey found that a majority of NF-1 
patients do recognize a need for clinical 
trials for MPNSTs (McQueen et al., 2008), 
but there are few avenues of treatment 
to assuage their concerns. In addition to 
the paucity of treatment options, the psy-
chological burden of neurofibromatosis 
leads to a chronic apprehension about 
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malignancy and death, due in part to the 
unpredictability of the disease (Redmann, 
2007). This leads to a decline in physician 
contact for adult NF-1 patients, limiting 
physicians’ abilities to monitor the devel-
opment of malignancies.
Predictive model
Sbidian et al. (2010, this issue) used 
univariate and multivariate analyses to 
identify four independent, quantitative 
variables that describe NF-1 patients 
with internal paraspinal neurofibromas. 
These factors include age and three easily 
recognizable dermal features: absence 
of cutaneous neuro fibromas, presence 
of subcutaneous neuro fibromas, and 
scarcity of café-au-lait macules. Each vari-
able is weighted according to predictive 
value in the NF-1Score, which is conve-
niently charted alongside the percentage 
likelihood that an individual assigned a 
given score has paraspinal neurofibro-
mas. Although the resulting score cannot 
predict an individual’s status with 100% 
accuracy, it does provide a compelling 
justification for increased scrutiny of NF-1 
patients with high scores.
concordance with current understanding
The fact that infrequent/absent cutane-
ous neurofibromas and café-au-lait spots 
are a predictor of internal neurofibromas 
at first seems paradoxical because these 
features are among the seven indicators 
used to diagnose NF-1. The heterogeneity 
of neurofibroma type, frequency, and dis-
tribution may be explained by identifying 
the ontological stage of differentiation at 
which the “second hit” mutation occurred 
(Figure 1). If the functioning NF-1 allele 
was inactivated early in the embryonic 
Schwann cell stages, when the neural 
crest stem cells had just migrated out of 
the neural tube, the founder population 
of tumor cells would remain within the 
Schwann cell lineage closer to the spinal 
cord and deep tissues. Neurofibromas 
derived from these tissues in the paraspi-
nal region would be more likely to associ-
ate with larger nerve plexuses, where they 
would retain their propensity to develop 
into MPNSTs or to migrate along periph-
eral nerves into subcutaneous tissues. 
Association with large nerves may amplify 
proliferative signals received by the NF-1−/− 
cells of the Schwann cell lineage, causing 
increased growth and greater risk of malig-
nancy. Conversely, dermal neurofibromas 
that arise near small cutaneous nerves and 
café-au-lait spots formed by melanocyte 
hyperproliferation in the dermis represent 
loss of heterogeneity events occurring 
closer to the terminal differentiation of 
these cell lines; thus, these features would 
be expected to appear less frequently 
in an individual with extensive internal 
plexiform neurofibromas.
Sbidian et al. (2010) are not the first to 
identify a relationship between NF-1 cuta-
neous/subcutaneous feature prevalence 
and disease progression. Khosrotehrani 
et al. (2005), using multivariate analysis 
to compare living and deceased NF-1 
patients in the Neurofibromatosis Institute 
Database (n = 703), determined that the 
presence of subcutaneous neurofibro-
mas was positively linked with mortal-
ity, of which a disproportionate cause 
was malignancy. Interestingly, whereas 
Khosrotehrani et al. (2005) found a signifi-
cant link between sex and mortality (high-
er in males), Sbidian et al. (2010) found no 
connection. Because Sbidian et al. (2010) 
focused only on predicting the presence 
of internal neurofibromas (associated with 
neoplasms but not other causes of death), 
this discrepancy suggests that sex differ-
ences in the susceptibility to alternative 
comorbidities of NF-1, such as cardio-
vascular disease, may exist. This possibility 
is supported by the fact that other sex dif-
ferences (i.e., cutaneous neurofibroma 
proliferation in response to female sex 
hormones during pregnancy) have been 
identified in NF-1. King et al. (2000) iden-
tified an association between pain and 
subcutaneous/cutaneous neurofibroma 
prevalence with MPNST development. It 
is possible that future refinements of the 
NF-1Score may incorporate other contrib-
utory factors identified by univariate test-
ing of a larger list of traits potentially asso-
ciated with internal neurofibromas, by 
studying the NF-1Score on a larger data-
set, or by attaining more detailed imag-
ing results of the thorax, spine, abdomen, 
and pelvis. Yet this initial manifestation of 
the NF-1Score is clearly a useful tool to 
improve NF-1 management.
Benefits of the nF-1Score for patients
Utilizing the NF-1Score can achieve 
several goals for improving patient 
care: (i) magnetic resonance imaging 
scans for indicated patients could 
identify tumors requiring further PET 
scan monitoring to identify latent 
MPNSTs for surgical treatment prior 
to the development of metastasis; 
(ii) more frequent visits with the 
treating physician could promote 
Figure 1. The cardinal clinical features of NF-1. Loss of heterozygosity of the neurofibromatosis type 1 
(NF-1) gene in the neural crest–derived tissues leads to a wide spectrum of clinical presentations, including 
pigment and neoplastic aberrations, which may be explained by identifying at which ontological stage of 
differentiation the “second hit” mutation occurred. Café-au-lait macules, axillary freckling, and cutaneous 
neurofibromas represent loss of heterogeneity events occurring in melanocyte and adult Schwann cell/
skin-derived progenitor lineage, respectively. On the other hand, internal and plexiform neurofibromas are 
congenital and thought to derive from embryonic Schwann cell lineage. They have the propensity to acquire 
additional genetic aberrations for transformation into malignant peripheral nerve-sheath tumors (MPNSTs).
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greater patient–physician trust and 
provide more opportunity for detecting 
warning signs indicative of malignant 
transformation in plexiform neurofibro-
mas, and (iii) NF-1 patient anxiety regard-
ing the unpredictable evolution of their 
disease could be alleviated partially by 
quantifiable assessment of their risk or 
surveillance screening in identified high-
risk populations. Furthermore, the authors 
note that the quantitative nature of the 
NF-1Score can be utilized in clinical trials: 
in determining patient inclusion criteria, 
quantifying disease severity, or categoriz-
ing participants by risk level for MPNSTs.
Adult patients judged to have “asymp-
tomatic” or mild NF-1 disease are not 
strongly encouraged to attend clinics in 
adulthood under current treatment pro-
tocols (Ferner et al., 2007); however, the 
NF-1Score parameters suggest that a lack 
of cutaneous features of NF-1 may place 
the patient at even greater risk for unfa-
vorable outcomes. This study may help 
to identify a population for which contin-
ued follow-up is clearly warranted. Adult 
NF-1 patients who decline regular care 
are encouraged to maintain familiarity 
with dangerous warning signs indicative 
of shifting neurofibroma status, includ-
ing intense/long-lasting pain, alteration 
in the consistency of a neurofibroma 
from soft to hard, and rapid neurofibroma 
growth (Ferner et al., 2007). Patients with 
high NF-1Scores could be instructed to 
pay special attention to these guidelines. 
Indeed, one of the recent foci in improving 
medical care has been to facilitate patient 
empowerment in disease management. 
A successful example of this has been the 
distribution of melanoma mole self-skin 
test cards to the public to aid in aware-
ness of the risk factors for melanoma and 
to instruct in self-examination. A similar 
card could be devised for NF-1 patients 
describing the neurofibroma “self-exam,” 
in addition to a list of risk factors for 
internal neuro fibromas, directing patients 
to contact their physicians if they meet 
three of the four predictive factors.
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Clinical Implications
•  The NF-1Score allows surveillance screening in identified high-risk populations.
•  NF-1 patients’ anxiety about the unpredictable nature of their disease may be 
alleviated partially by a quantifiable assessment of risk.
•  More frequent visits could promote patient–physician trust and provide 
opportunities for detecting signs of malignant transformation.
•  MRI scans could identify tumors requiring further PET scan monitoring.
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X-Linked Inhibitor of Apoptosis 
Protein as a Therapeutic Target  
in Metastatic Melanoma
Fang Tian1 and Sam W. Lee1
Melanoma is the most dangerous type of skin cancer, with notorious resistance 
to current chemotherapy and immunotherapy. In this issue, Hiscutt et al. report 
on the prognostic significance of X-linked inhibitor of apoptosis protein (XIAP) 
in melanoma. The finding that XIAP inhibition significantly increases endoplas-
mic reticulum stress-mediated apoptosis in melanoma cells suggests that XIAP 
is a potential therapeutic target for melanoma therapy.
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XIaP as a potential biomarker  
of melanoma
Skin cancer is one of the most 
common human malignancies, and 
its incidence is rising globally at an 
alarming rate. Basal cell carcinoma, 
squamous cell carcinoma, and mela-
noma are three major forms of skin 
